Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabinoid ophthalmic formulation
- Development stage
- Preclinical
- Lead developer
- Incannex Healthcare
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
The cannabinoid ophthalmic formulation is a preclinical-stage therapeutic developed by APIRx Pharmaceuticals (acquired by Incannex Healthcare) for the treatment of glaucoma and conjunctivitis. This aqueous small molecule formulation consists of a specific combination of cannabinoids, including tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG). It is designed for ophthalmic administration to reduce intraocular pressure in glaucoma patients and provide anti-inflammatory and anti-bacterial relief for conjunctival inflammation. The product leverages the therapeutic properties of cannabinoids acting on the endocannabinoid system within the eye to manage ocular conditions.
- Other names
- ophthalmic cannabinoid formulation
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on cannabinoid ophthalmic formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabinoid ophthalmic formulation.